OverviewChartNewsTraderScreen

Discount Zertifikat auf die Aktie.../  DE000HD05WJ8  /

gettex Zertifikate
7/10/2024  3:46:09 PM Chg.+0.600 Bid4:41:24 PM Ask4:41:24 PM Underlying Strike price Expiration date Option type
91.670EUR +0.66% 92.000
Bid Size: 4,000		 92.020
Ask Size: 4,000		 SANOFI SA INHABER ... - - 9/27/2024 Call
GlobeNewswire 6/28 Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Di...
TeleTrader 6/27 Europe opens mixed before consumer confidence data
GlobeNewswire 6/27 Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
GlobeNewswire 6/26 Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esoph...
GlobeNewswire 6/26 Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic e...
GlobeNewswire 6/21 Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s ...
GlobeNewswire 6/21 Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusi...
GlobeNewswire 6/20 Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa
GlobeNewswire 6/18 Belharra Therapeutics Announces Strategic Collaboration with Sanofi to Advance Discovery of Novel Sm...
GlobeNewswire 6/11 Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...
GlobeNewswire 6/3 Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival ...
GlobeNewswire 5/31 Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
GlobeNewswire 5/31 Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire 5/31 Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
GlobeNewswire 5/31 Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...
GlobeNewswire 5/31 Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...
GlobeNewswire 5/30 Press Release: Sanofi completes acquisition of Inhibrx, Inc.
GlobeNewswire 5/27 Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible ...
GlobeNewswire 5/23 CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments
GlobeNewswire 5/21 Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
GlobeNewswire 5/20 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire 5/20 Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire 5/20 Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...
GlobeNewswire 5/13 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire 5/13 Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...